Journal of the Pancreas Open Access

  • ISSN: 1590-8577
  • Journal h-index: 80
  • Journal CiteScore: 29.12
  • Journal Impact Factor: 19.45*
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Reach us +44 7460731551

Abstract

Low-Dose Metronomic Capecitabine (Xeloda) for Treatment of Metastatic Cholangiocarcinoma : Case Reports and Review of the Literature

Bergthor Bärnsson, Maria Albertsson, Per Sandsträm

Background Metastatic Cholangiocarcinoma is a disease with a dismal prognosis. Treatment options are few, survival short and the side effects of treatments are burdensome. Metronomic chemotherapy can offer tumour regression and palliation. In this study we explore the responses of three patients to this treatment method in cases where conventional chemotherapy treatment has failed. Methods Three patients diagnosed with metastatic cholangiocarcinoma are described. All patients have been treated with metronomic Xeloda (500 mg x 2). The available literature for metronomic treatment is reviewed. Results Tumour regression or stable diseases for long periods were seen in all three cases. Toxicity noticed was Grade I or II. Conclusions Metronomic chemotherapy can be a therapeutic alternative in selected cases of metastatic cholangiocarcinoma, especially where toxicity limits treatment alternatives for highly motivated patients.